

10/800, 137

FILE 'HOME' ENTERED AT 17:49:46 ON 29 APR 2007

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 17:50:24 ON 29 APR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 17:50:24 ON 29 APR 2007

FILE 'CAPLUS' ENTERED AT 17:50:24 ON 29 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 17:50:24 ON 29 APR 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 17:50:24 ON 29 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s nucleic acid (5a0 (extract? or isolat?)

MISSING OPERATOR 'ACID (5A0'

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s nucleic acid (5a) (extract? or isolat?)

3 FILES SEARCHED...

L1 60501 NUCLEIC ACID (5A) (EXTRACT? OR ISOLAT?)

=> s l1 and surfactant

L2 6130 L1 AND SURFACTANT

=> s l2 and cationic surfactant

L3 60 L2 AND CATIONIC SURFACTANT

=> s l3 and protease

L4 27 L3 AND PROTEASE

=> s l4 and polymer

L5 18 L4 AND POLYMER

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 17 DUP REM L5 (1 DUPLICATE REMOVED)

=> s l6 and buffer

L7 17 L6 AND BUFFER

=> d l7 bib abs 1-17

L7 ANSWER 1 OF 17 WPIDS COPYRIGHT 2007

THE THOMSON CORP on STN

AN 2005-099961 [11] WPIDS

CR 2003-370730

DNC C2005-033420 [11]

DNN N2005-086813 [11]

TI Isolating nucleic acids from a biological sample by combining the sample
with at least one cationic surfactant, at least one
protease, and a buffer, to form a reaction composition

DC A89; B04; D16; P53
 IN GREENFIELD L; MONTESCLAROS L
 PA (APPL-N) APPLERA CORP
 CYC 1
 PIA US 20050009045 A1 20050113 (200511)* EN 58[30]
 ADT US 20050009045 A1 CIP of US 2000-724613 20001128; US 20050009045 A1 Cont
 of US 2001-997169 20011128; US 20050009045 A1 US 2004-800137 20040311
 FDT US 20050009045 A1 Cont of US 6762027 B
 PRAI US 2004-800137 20040311
 US 2000-724613 20001128
 US 2001-997169 20011128
 AN 2005-099961 [11] WPIDS
 CR 2003-370730
 AB US 20050009045 A1 UPAB: 20050708
 NOVELTY - Isolating nucleic acids from a biological sample comprising
 combining the sample with at least one cationic
 surfactant, at least one protease, and a buffer
 , to form a reaction composition, incubating the reaction composition at a
 temperature suitable for releasing nucleic acid from
 the biological sample, and isolating the released
 nucleic acid, is new.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
 (1) releasing nucleic acids from a biological sample, comprising:
 (a) combining the sample with at least one cationic
 surfactant, at least one protease, and a buffer
 , to form a reaction composition; and
 (b) incubating the reaction composition at a temperature suitable
 for releasing the nucleic acids from the biological sample; and
 (2) a kit for obtaining nucleic acid from a biological sample
 comprising at least one cationic surfactant and at
 least one protease.
 USE - The methods and compositions of the present invention are
 useful for isolating and releasing nucleic acids from biological samples,
 including whole tissue.
 ADVANTAGE - The methods of isolating nucleic acids in the present
 invention, as compared to prior art, reduces the time needed for sample
 preparation, decreases potential safety risks posed by multi-step
 procedures and provides high integrity high molecular weight nucleic
 acids.

L7 ANSWER 2 OF 17 USPATFULL on STN
 AN 2006:218762 USPATFULL
 TI Cartridge retaining mechanism for nucleic acid
 extracting apparatus
 IN Inana, Katsuya, Asaka-shi, JAPAN
 PA FUJI PHOTO FILM CO., LTD. (non-U.S. corporation)
 PI US 2006186037 A1 20060824
 AI US 2006-355990 A1 20060217 (11)
 PRAI JP 2005-43965 20050221
 DT Utility
 FS APPLICATION
 LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747,
 US
 CLMN Number of Claims: 4
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Page(s)
 LN.CNT 1983
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A cartridge retaining mechanism equipped in a nucleic
 acid extracting apparatus for extracting a
 nucleic acid, the mechanism comprising: a cartridge
 that comprises: a cartridge main body that has a cylindrical shape with
 a bottom, and the bottom is shaped in a funnel shape; a nucleic
 acid-adsorbing solid carrier that traps a nucleic acid, and the carrier

is disposed at the bottom; and a cartridge cap that is detachably mounted on an open end of the cartridge main body, a supporting part that supports the cartridge; and a pressure-proof retaining part that pushes the cartridge cap, wherein a cylindrical rib with a diameter smaller than a diameter of the cartridge main body is formed on an upper plane of the cartridge cap so that the cylindrical rib protrudes from the upper plane; a nozzle-receiving opening to which a pressure nozzle is pressed is formed at the cylindrical rib; and an aperture through which the cylindrical rib is inserted is formed in the pressure-proof retaining part, and wherein when the pressure nozzle is pressed to the nozzle-receiving opening, along with the nozzle-receiving opening being exposed from the aperture, the cartridge cap is pressed by the pressure-proof retaining part and simultaneously the cartridge main body is supported by the supporting part.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 17 USPATFULL on STN
AN 2006:188191 USPATFULL
TI Method for administering a cytokine to the central nervous system and the lymphatic system
IN Frey, William H. II, North Oaks, MN, UNITED STATES
PI US 2006159626 A1 20060720
AI US 2005-222669 A1 20050909 (11)
RLI Division of Ser. No. US 2002-102163, filed on 20 Mar 2002, GRANTED, Pat. No. US 6991785 Continuation of Ser. No. US 2000-733168, filed on 8 Dec 2000, ABANDONED
PRAI US 1999-200708P 19991209 (60)
DT Utility
FS APPLICATION
LREP Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1-20
DRWN 1 Drawing Page(s)
LN.CNT 2849

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon- β and its muteins such as IFN- β .sub.ser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 17 USPATFULL on STN
AN 2006:158691 USPATFULL
TI Methods for producing block copolymer/amphiphilic particles
IN Geall, Andrew, San Marcos, CA, UNITED STATES
PA Vical Incorporated, San Diego, CA, UNITED STATES (U.S. corporation)
PI US 2006134221 A1 20060622
AI US 2005-292280 A1 20051202 (11)
PRAI US 2004-632612P 20041203 (60)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1-117
DRWN 4 Drawing Page(s)

LN.CNT 4002

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, compositions comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell delivery particles and pharmaceutical component-particle dispersions produced by the claimed methods and compositions comprising same. In certain embodiments, the cell delivery particles may further comprise co-lipids. The invention further relates to methods of generating an immune response, treating or preventing a disease or condition, or delivering a biologically active molecule to cells in vitro comprising administration of the pharmaceutical compositions described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 17 USPATFULL on STN

AN 2006:80498 USPATFULL

TI Microdevice for performing method of separating and purifying nucleic acid

IN Makino, Yoshihiko, Asaka-shi, JAPAN

Sakaino, Yoshiki, Asaka-shi, JAPAN

Sudo, Yukio, Minami-Ashigara-shi, JAPAN

Abe, Yoshihiko, Asaka-shi, JAPAN

PA Fuji Photo Film Co., Ltd. (non-U.S. corporation)

PI US 2006068491 A1 20060330

AI US 2005-227245 A1 20050916 (11)

PRAI JP 2004-278070 20040924

DT Utility

FS APPLICATION

LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747, US

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 1532

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A microdevice for performing a method for separating and purifying a nucleic acid, the microdevice comprising: at least one opening; and at least one channel for passing a sample solution, wherein the method comprises: (A) a step of bringing a nucleic acid-containing sample solution into contact with a nucleic acid-adsorbing support having a function of adsorbing a nucleic acid; (B) a step of washing the nucleic acid-adsorbing support with a washing solution in a state of a nucleic acid being adsorbed to the support; and (C) a step of desorbing the nucleic acid from the nucleic acid-adsorbing support by a recovering solution, thereby purifying the nucleic acid; an apparatus for utilizing the microdevice; and a reagent kit for use in the microdevice.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 17 USPATFULL on STN

AN 2006:60634 USPATFULL

TI Method for separating and purifying nucleic acid

IN Iwaki, Yoshihide, Asaka-shi, JAPAN

Mori, Toshihiro, Asaka-shi, JAPAN

PA Fuji Photo Film Co., Ltd. (non-U.S. corporation)

PI US 2006051799 A1 20060309

AI US 2005-217339 A1 20050902 (11)

PRAI JP 2004-257202 20040903

JP 2005-253576 20050901

DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747,
US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1848

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acid contained in a sample is highly efficiently recovered at a high recovery ratio by a method for separating and purifying nucleic acid using whole blood as the sample, which is a method for separating and purifying nucleic acid, comprising: preparing a sample solution containing nucleic acid; putting the sample solution containing nucleic acid in contact with a solid phase to allow nucleic acid to be adsorbed to the solid phase; putting a washing solution in contact with the solid phase to wash the solid phase at the state of nucleic acid adsorbed thereon; and putting a elution solution in contact with the solid phase to allow nucleic acid to be desorbed from the solid phase, wherein the step of preparing a sample solution containing nucleic acid comprises at least one selected from the group consisting of vortexing, mixing with inversion, and pipetting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 17 USPATFULL on STN
AN 2006:43228 USPATFULL
TI Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
IN Greenfield, I. Lawrence, San Mateo, CA, UNITED STATES
PA Applera Corporation, Foster City, CA, UNITED STATES (U.S. corporation)
PI US 7001724 B1 20060221
AI US 2000-724613 20001128 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Bortner, Scott, Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1556

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for releasing and for isolating nucleic acids from biological samples, preferably from whole tissue, using cationic surfactants and proteases. The surfactant-protease combinations, when used with whole tissue, macerate the tissue, lyse individual cells, release nucleic acids, and inactivate nucleases. Kits for isolating nucleic acids from biological samples, particularly from whole tissue, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 17 USPATFULL on STN
AN 2006:40694 USPATFULL
TI Double-stranded rna structures and constructs, and methods for generating and using the same
IN Pachuk, Catherine J., Lansdale, PA, UNITED STATES
Satishchandran, C., Lansdale, PA, UNITED STATES
McCallus, Daniel Edward, Oaks, PA, UNITED STATES
PI US 2006035344 A1 20060216
AI US 2003-531349 A1 20031020 (10)
WO 2003-US33466 20031020
20050415 PCT 371 date
PRAI US 2002-60419532 20021018

US 2003-60421757 20021028
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 68
ECL Exemplary Claim: 1-107
DRWN 19 Drawing Page(s)
LN.CNT 6620

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel double-stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell of animal (e.g., a mammal such as a human) without inducing toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides method for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 17 USPATFULL on STN
AN 2006:15795 USPATFULL
TI Stable protein storage and stable nucleic acid storage in recoverable form
IN Hogan, Michael, Tucson, AZ, UNITED STATES
Davis, James C., Carlsbad, CA, UNITED STATES
PI US 2006014177 A1 20060119
AI US 2005-137806 A1 20050524 (11)
PRAI US 2004-574274P 20040524 (60)
DT Utility
FS APPLICATION
LREP PILLSBURY WINTHROP SHAW PITTMAN LLP, ATTENTION: DOCKETING DEPARTMENT, 11682 EL CAMINO REAL, SUITE 200, SAN DIEGO, CA, 92130, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 4170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for storage of biomolecules. The biomolecules are stored via absorption to a substrate. Absorbed biomolecules can be eluted or recovered from the substrate at a future time, and optionally be subjected to a subsequent analysis or application. Biomolecules absorbed to a substrate for storage may also optionally be preserved, i.e., the absorbed biomolecule is resistant to or resists degradation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 17 USPATFULL on STN
AN 2005:131198 USPATFULL
TI Method of isolating and purifying a nucleic acid
IN Makino, Yoshihiko, Asaka-shi, JAPAN
PA Fuji Photo Film Co., Ltd. (non-U.S. corporation)
PI US 2005112658 A1 20050526
AI US 2004-975469 A1 20041029 (10)
PRAI JP 2003-373024 20031031
JP 2003-373111 20031031
JP 2004-277933 20040924
DT Utility
FS APPLICATION

LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747,
US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1680

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of isolating and purifying a nucleic acid, comprises the steps of: (1a) passing a sample solution containing a nucleic acid through a nucleic acid-adsorptive porous membrane to adsorb the nucleic acid to the nucleic acid-adsorptive porous membrane under a specific condition; (2a) passing a wash solution through the nucleic acid-adsorptive porous membrane to wash the nucleic acid-adsorptive porous membrane while adsorbing the nucleic acid under a specific condition; and (3a) passing a elution solution through the nucleic acid-adsorptive porous membrane to desorb the nucleic acid from the nucleic acid-adsorptive porous membrane under a specific condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 17 USPATFULL on STN
AN 2005:43624 USPATFULL
TI Method of purifying nucleic acid using nonwoven fabric and detection method
IN Kanno, Kimiyoshi, Shizuoka, JAPAN
Oda, Naozumi, Shizuoka, JAPAN
Aritomi, Masaharu, Shizuoka, JAPAN
Sato, Akiko, Shizuoka, JAPAN
PI US 2005037351 A1 20050217
AI US 2004-483071 A1 20040108 (10)
WO 2002-JP6939 20020709
PRAI JP 2001-208514 20010709
JP 2001-364878 20011129
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 29 Drawing Page(s)
LN.CNT 3013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of separating and purifying nucleic acids from samples containing cells, such as blood and culture solutions. According to the method of the invention, a cell extract obtained by cell disruption is adsorbed by a filter made of a nonwoven fabric and the nucleic acid is eluted after washing the filter. Alkaline conditions of pH 12 or higher may be employed for elution of the nucleic acid, or the filter-adsorbed nucleic acid may be eluted by treatment with active oxygen or by using a surfactant. Nucleic acids separated and purified by the method of the invention can be used in nucleic acid amplification and nucleic acid sequence analysis techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 17 USPATFULL on STN
AN 2005:10902 USPATFULL
TI Methods and kits for obtaining nucleic acid from biological samples
IN Montesclaros, Luz, Pittsburg, CA, UNITED STATES
Greenfield, I. Lawrence, San Mateo, CA, UNITED STATES
PA Applera Corporation, Foster City, CA (U.S. corporation)
PI US 2005009036 A1 20050113
AI US 2003-618493 A1 20030711 (10)
DT Utility
FS APPLICATION

LREP MILA KASAN, PATENT DEPT., APPLIED BIOSYSTEMS, 850 LINCOLN CENTRE DRIVE,
FOSTER CITY, CA, 94404
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 1591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and kits for isolating nucleic acids from a sample, typically a biological sample are disclosed. In certain embodiments, the methods and kits of the invention comprise at least one protease and at least one solid phase. In certain embodiments, the methods and kits of the invention comprise at least one chaotrope and at least one solid phase. In certain embodiments, the inventive methods and kits further comprise at least one chaotrope, at least one zwitterionic compound, at least one cationic detergent, at least one non-ionic detergent, or combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 17 USPATFULL on STN
AN 2003:337233 USPATFULL
TI Mutant genes in Familial British Dementia and Familial Danish Dementia
IN Ghiso, Jorge, Elmhurst, NY, United States
Vidal, Ruben, Great Neck, NY, United States
Frangione, Blas, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 6670195 B1 20031230
AI US 2000-579012 20000526 (9)
PRAI US 1999-136238P 19990526 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Falk, Anne-Marie
LREP Venable LLP, Livnat, Shmuel
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2973

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Two novel mutant amyloid protein precursors (ABriPP and ADanPP) and their amyloid peptides (ABri and ADan) associated with Familial British Dementia and Familial Danish Dementia, respectively, are disclosed. Genetic constructs comprising DNA encoding these proteins is used to produced transgenic mammals that are useful models for neurological diseases associated with amyloid deposits, neurofibrillary tangles, non-neuritic plaques, neuronal degeneration and behavioral deficits characteristic of dementia and other symptoms of the human diseases. These models are used for testing potential therapeutic agents and methods. Also provided is a DNA-based test for detecting the mutations, the mutant proteins and peptides, antibodies specific for the proteins and peptides. Immunoassays permit detection of the mutant proteins, particularly in affected brain tissue, or detection of an antibody specific for a mutant peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 17 USPATFULL on STN
AN 2002:314662 USPATFULL
TI Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
IN Greenfield, Lawrence, San Mateo, CA, UNITED STATES
Montesclaros, Luz, Pittsburg, CA, UNITED STATES
PI US 2002177139 A1 20021128
US 6762027 B2 20040713
AI US 2001-997169 A1 20011128 (9)

RLI Continuation-in-part of Ser. No. US 2000-724613, filed on 28 Nov 2000,
PENDING
DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 2457

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions and methods for isolating nucleic
acids from biological samples, including whole tissue. The invention
also provides kits for isolating nucleic acids from biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 17 USPATFULL on STN
AN 2002:258404 USPATFULL
TI Method for administering a cytokine to the central nervous system and
the lymphatic system
IN Frey, William H., II, North Oaks, MN, UNITED STATES
PA Chiron Corporation (U.S. corporation)
PI US 2002141971 A1 20021003
US 6991785 B2 20060131
AI US 2002-102163 A1 20020320 (10)
RLI Continuation of Ser. No. US 2000-733168, filed on 8 Dec 2000, PENDING
PRAI US 1999-200708P 19991209 (60)
DT Utility
FS APPLICATION
LREP Corporate Patent Counsel, Intellectual Property, CHIRON CORPORATION,
P.O. Box 8097, Emeryville, CA, 94662-8097
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2947

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for delivering cytokines
to the central nervous system and the lymphatic system by way of a
tissue innervated by the trigeminal nerve and/or olfactory nerve.
Cytokines include tumor necrosis factors, interleukins, interferons,
particularly interferon- β and its muteins such as
IFN- β .sub.ser17. Such a method of delivery can be useful in the
treatment of central nervous system disorders, brain disorders,
proliferative, viral, and/or autoimmune disorders such as Sjogren's
disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 17 USPATFULL on STN
AN 2002:194880 USPATFULL
TI Reverse micelles for delivery of nucleic acids
IN Monahan, Sean D., Madison, WI, United States
Wolff, Jon A., Madison, WI, United States
Slattum, Paul M., Madison, WI, United States
Hagstrom, James E., Madison, WI, United States
Budker, Vladimir G., Madison, WI, United States
PA Mirus Corporation, Madison, WI, United States (U.S. corporation)
PI US 6429200 B1 20020806
AI US 1999-354957 19990716 (9)
PRAI US 1998-93227P 19980717 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Guzo, David

LREP Johnson, Mark K.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1480

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A complex is described for delivery to a cell comprising inserting a nucleic acid into a reverse micelle. The reverse micelle has the property to compact the nucleic acid for easier delivery. Other molecules are used to interact with the nucleic acid--micelle complex to further enhance delivery such as a surfactant having a disulfide bond.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 17 USPATFULL on STN
AN 2001:211923 USPATFULL
TI Method for administering a cytokine to the central nervous system and the lymphatic system
IN Frey, William H., II, North Oaks, MN, United States
PA Chiron Corporation (U.S. corporation)
PI US 2001043915 A1 20011122
AI US 2000-733168 A1 20001208 (9)
PRAI US 1999-200708P 19991209 (60)
DT Utility
FS APPLICATION
LREP Joseph H. Guth, Esq., Corporate Patent Counsel, CHIRON CORPORATION, P.O. Box 8097, Emeryville, CA, 94662-8097
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon- β and its muteins such as IFN- β .sub.ser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.